ADMA
Income statement / Annual
Last year (2023), ADMA Biologics, Inc.'s total revenue was $258.21 M,
an increase of 67.59% from the previous year.
In 2023, ADMA Biologics, Inc.'s net income was -$28.24 M.
See ADMA Biologics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$258.21 M
|
$154.08 M
|
$80.94 M
|
$42.22 M
|
$29.35 M
|
$16.99 M
|
$22.76 M
|
$10.66 M
|
$7.18 M
|
$5.92 M
|
| Cost of Revenue |
$170.00 M |
$118.81 M |
$79.77 M |
$61.29 M |
$39.50 M |
$42.19 M |
$29.16 M |
$6.36 M |
$4.31 M |
$3.74 M |
| Gross Profit |
$88.22 M |
$35.27 M |
$1.17 M |
-$19.07 M |
-$10.16 M |
-$25.21 M |
-$6.40 M |
$4.30 M |
$2.87 M |
$2.17 M |
| Gross Profit Ratio |
0.34 |
0.23 |
0.01 |
-0.45 |
-0.35 |
-1.48 |
-0.28 |
0.4 |
0.4 |
0.37 |
| Research and Development
Expenses |
$3.30 M
|
$3.61 M
|
$3.65 M
|
$5.91 M
|
$2.34 M
|
$3.93 M
|
$6.23 M
|
$7.69 M
|
$7.02 M
|
$9.52 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$22.50 M
|
$18.09 M
|
$8.49 M
|
$6.75 M
|
$4.82 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$59.02 M
|
$52.46 M
|
$42.90 M
|
$35.05 M
|
$25.91 M
|
$22.50 M
|
$18.09 M
|
$8.49 M
|
$6.75 M
|
$4.82 M
|
| Other Expenses |
$4.99 M |
$18.56 M |
$13.00 M |
$4.89 M |
$3.01 M |
-$127,121.00 |
-$10,144.00 |
$4,496.00 |
$4.62 M |
-$74,356.00 |
| Operating Expenses |
$66.59 M |
$74.63 M |
$59.55 M |
$45.84 M |
$31.27 M |
$35.08 M |
$32.06 M |
$21.63 M |
$18.38 M |
$18.19 M |
| Cost And Expenses |
$236.58 M |
$193.44 M |
$139.32 M |
$107.13 M |
$70.77 M |
$77.27 M |
$61.23 M |
$27.99 M |
$22.69 M |
$21.93 M |
| Interest Income |
$1.62 M |
$44,833.00 |
$34,532.00 |
$288,126.00 |
$800,785.00 |
$195,403.00 |
$57,228.00 |
$50,317.00 |
$37,830.00 |
$14,217.00 |
| Interest Expense |
$25.03 M |
$19.28 M |
$13.06 M |
$11.99 M |
$8.99 M |
$5.52 M |
$3.29 M |
$2.24 M |
$1.84 M |
$1.29 M |
| Depreciation &
Amortization |
$8.33 M
|
$7.11 M
|
$5.50 M
|
$3.94 M
|
$3.26 M
|
$3.45 M
|
$1.23 M
|
$469,576.00
|
$469,821.00
|
$247,852.00
|
| EBITDA |
$5.12 M
|
-$39.72 M
|
-$53.33 M
|
-$59.82 M
|
-$36.03 M
|
-$56.77 M
|
-$39.31 M
|
-$16.81 M
|
-$15.66 M
|
-$15.83 M
|
| EBITDA Ratio |
0.02 |
-0.25 |
-0.72 |
-1.52 |
-1.36 |
-3.34 |
-1.63 |
-1.58 |
-2.09 |
-2.72 |
| Operating Income Ratio
|
0.08
|
-0.26
|
-0.72
|
-1.54
|
-1.41
|
-3.55
|
-1.73
|
-1.63
|
-2.16
|
-2.71
|
| Total Other
Income/Expenses Net |
-$49.87 M
|
-$26.75 M
|
-$13.51 M
|
-$10.83 M
|
-$6.85 M
|
-$5.45 M
|
-$4.45 M
|
-$2.18 M
|
-$2.46 M
|
-$1.35 M
|
| Income Before Tax |
-$28.24 M |
-$65.90 M |
-$71.65 M |
-$75.75 M |
-$48.28 M |
-$65.74 M |
-$43.76 M |
-$19.52 M |
-$17.97 M |
-$17.36 M |
| Income Before Tax Ratio
|
-0.11
|
-0.43
|
-0.89
|
-1.79
|
-1.65
|
-3.87
|
-1.92
|
-1.83
|
-2.5
|
-2.94
|
| Income Tax Expense |
$0.00 |
$19.28 M |
$12.81 M |
$11.86 M |
$8.77 M |
$5.45 M |
$4.45 M |
$2.18 M |
$2.46 M |
-$551,724.00 |
| Net Income |
-$28.24 M |
-$85.18 M |
-$84.45 M |
-$87.61 M |
-$57.05 M |
-$65.74 M |
-$43.76 M |
-$19.52 M |
-$17.97 M |
-$16.81 M |
| Net Income Ratio |
-0.11 |
-0.55 |
-1.04 |
-2.07 |
-1.94 |
-3.87 |
-1.92 |
-1.83 |
-2.5 |
-2.84 |
| EPS |
-0.13 |
-0.43 |
-0.61 |
-1.02 |
-1.05 |
-1.45 |
-1.91 |
-1.61 |
-1.73 |
-1.81 |
| EPS Diluted |
-0.13 |
-0.43 |
-0.61 |
-1.02 |
-1.05 |
-1.45 |
-1.91 |
-1.61 |
-1.73 |
-1.81 |
| Weighted Average Shares
Out |
$223.98 M
|
$197.87 M
|
$139.58 M
|
$86.15 M
|
$54.35 M
|
$45.19 M
|
$22.90 M
|
$12.15 M
|
$10.41 M
|
$9.29 M
|
| Weighted Average Shares
Out Diluted |
$223.98 M
|
$197.87 M
|
$139.58 M
|
$86.15 M
|
$54.35 M
|
$45.19 M
|
$22.90 M
|
$12.15 M
|
$10.41 M
|
$9.29 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
